Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MIF | P14174 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.38 |
| ▸ | NAT1 | P18440 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3438493 | 1.00 | EGFR (0.46) | EGFRGAAALDH1A1KDM4EMAPT | |
| SCHEMBL3438061 | 0.90 | EGFR (0.46) | EGFRGAAALDH1A1KDM4EMAPT | |
| SCHEMBL3438060 | 0.90 | EGFR (0.46) | EGFRGAAALDH1A1KDM4EMAPT | |
| SCHEMBL3438057 | 0.87 | ALDH1A1 (0.48) | EGFRGAAALDH1A1KDM4EMAPT | |
| SCHEMBL3438059 | 0.87 | ALDH1A1 (0.48) | EGFRGAAALDH1A1KDM4EMAPT | |
| SCHEMBL3438195 | 0.83 | MIF (0.45) | EGFRGAAALDH1A1KDM4EMAPT | |
| SCHEMBL3438197 | 0.83 | MIF (0.45) | EGFRGAAALDH1A1KDM4EMAPT | |
| SCHEMBL3438576 | 0.81 | KMT2A (0.50) | EGFRALDH1A1KDM4EMAPTMIF | |
| SCHEMBL3438575 | 0.81 | KMT2A (0.50) | EGFRALDH1A1KDM4EMAPTMIF | |
| SCHEMBL3438473 | 0.81 | GAA (0.49) | EGFRGAAALDH1A1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807856-B2 | Process for production of 2-Benzylphenol compound | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 2010-10-05 | — | — | US | disclosed |
| US-20080194882-A1 | Process For Production of 2-Benzylphenol Compound | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 2008-08-14 | — | — | US | disclosed |
| EP-1810957-A1 | METHOD FOR PRODUCING 2-BENZYLPHENOL COMPOUND | Ihara Chemical Industry Co., Ltd. (JP) | 2007-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194882-A1 | Process For Production of 2-Benzylphenol Compound | CYP1B1, CYP4B1, CYP1A1 | EGFR 3278/4885GAA 3701/4885ALDH1A1 1026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.